Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Accumulated Expenses (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Other Accumulated Expenses for 7 consecutive years, with $129000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 13.16% to $129000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129000.0 through Dec 2025, up 13.16% year-over-year, with the annual reading at $129000.0 for FY2025, 13.16% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $129000.0 at 4D Molecular Therapeutics, up from $108000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $1.8 million in Q4 2021, with the low at $45000.0 in Q1 2023.
  • Average Other Accumulated Expenses over 5 years is $285650.0, with a median of $151500.0 recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 260.49% in 2021, then crashed 93.18% in 2023.
  • Over 5 years, Other Accumulated Expenses stood at $1.8 million in 2021, then tumbled by 78.42% to $382000.0 in 2022, then crashed by 72.77% to $104000.0 in 2023, then grew by 9.62% to $114000.0 in 2024, then rose by 13.16% to $129000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $129000.0, $108000.0, and $102000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.